Top Markets
Coin of the day
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
Rang in aandelen #24454
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Aandeelprijs
$0.78611575
Marktkapitalisatie
$60.45M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-12.06%
Land
NO
Handel Lytix Biopharma AS (LYTIX)

Categorie

Koersgeschiedenis voor Lytix Biopharma AS (LYTIX)
Hoogste slotkoers: $0.83 op 2026-08-01

Laagste slotkoers: $1.84 op 2021-06-01
Koersgeschiedenis van Lytix Biopharma AS van 2021 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) -4.78%
2025 65.95%
2024 18.94%
2023 -38.40%
2022 -48.20%
2021 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$549.38 38.22%
US
$1.05K 58.78%
NL
$145.41 454.58%
US
$118.70 -18.24%
AU
$770.19 9.84%
CH